Lithuania
Sanobiotec, founded in 2018, stands as a prominent figure in the Biotechnology industry, excelling as a leading cannabinoid manufacturer. The company boasts a presence in the USA, EU, and Japan, with major hubs in Chicago, Vilnius, and Tokyo.
The slogan, "Leading cannabinoid manufacturer in the USA, EU, and Japan. Looking for CBN, CBC, CBDV, or CBD Isolate? Let's connect.", encapsulates their market reach and specialized focus on premium minor cannabinoids like CBN, CBL, CBV, CBG, CBGA, CBDV, CBC, and CBD. Their products are positioned for superior quality, evidenced by certifications including ISO 22716:2007 and ISO 9001:2015.
By utilizing ISO 17025 certified third-party labs, Sanobiotec ensures rigorous testing for quality assurance. The company promises competitive prices and next-day delivery, appealing to potential distributors and partners. However, it's worth noting that the company's last known investment details or investor involvement remains undisclosed.
In summary, Sanobiotec positions itself as a potential gem in the cannabinoid sector by combining certified quality and global reach, presenting a compelling opportunity for discerning investors seeking to capitalize on the growing interest in biotechnology solutions.
